Use of Biochips has brought about a transition in the field of Drug Discovery and Research

The development of biochips has been able to influence the growth of automated processes and miniaturization of products throughout all major sectors covered in report. In the healthcare sector, biochips are largely used in laboratories for drug discovery and research for symptoms of diseases. The laboratory equipments have become smaller and efficient due to the use of biochips. In addition, biochips are capable of performing multiple biochemical reactions simultaneously and easily. Moreover, it helps in identifying and detecting gene sequences and analyzing proteins in animal and human bodies. Biochips are largely used in in-vitro diagnostics, where it detects symptoms of diseases and provides cure for the same. It is also capable of carrying out tests for analyzing pandemics, drug tests, glucose monitoring, diabetic control and diagnosis of various diseases. In addition, biochips ensure accurate and precise modelling physiological situations for both drug development and fundamental research. Moreover, it helps in carrying out high volume tests for numerous aspects in drug discovery and development. In the dynamic business environment where numerous technological advancements are taking place each day, it is necessary for the biochips manufacturing companies to align its strategies with the technological shifts in order to achieve a sustainable growth and profitable returns. Moreover, the use of biochips has revolutionized molecular diagnostics in identifying the presence of organisms such as bacteria and virus in patient samples, detecting genetic disorders and monitoring of viral responses to therapy. Home monitoring biochip systems are expected to detect and provide healthcare solutions with the help of computers to patients in their homes. For initial advice regarding treatment, biochip-enabled computer systems would be able to transmit to the hospital using wireless telemetry, thereby providing the individual with a suitable cure without any delay and effort.

                                                       BIOCHIPS MARKET

 However, there are a few factors, which are inhibiting the growth of biochips market globally. Companies that manufacture biochips have to comply with a number of regulations relating to medical devices such as Clinical and Laboratory Standards Institute (CLSI) and United States Pharmacopeia (USP) among others, which poses a major challenge for a large number of companies. Microarrays, which are a two-dimensional grid of biosensors, are the essential components of biochips. The sensors are placed on a solid substrate that may be active or passive. Passive substrates are either silicon or glass, which are largely used because silicon and glass have well-established micro fabrication and micromachining processes. Passive substrates require silica etching, which is a time consuming process and entails the use of special resources and a large amount of chemical solvents that pose a threat to environmental safety. The environmental hazards related to the use of glass and silicon as popular substrates for biochips are expected to inhibit the global biochips market significantly.

The biochips market has huge scope and opportunity in the emerging markets of Asia Pacific and Rest of the World (RoW). Countries such as India, China, Japan, and Australia are the key biochips markets falling under the Asia Pacific and RoW regions. Biochips are increasingly finding application in the biotechnology and biomedical devices industries. Molecular diagnostics and drug discovery are the major driving factors influencing the growth of the industries. Moreover, venture capital firms globally are investing heavily in biochip technology.

In North America, the U.S. has been showing significant growth over the years and is one of the dominant biochips markets globally. Japan, China and India are the largest contributors to the biochips market in the Asia Pacific region. In Europe, Germany and U.K. are the largest regional markets for biochips because of increasing investments in biochips technology and growth in the healthcare sector. Latin America and UAE are showing substantial growth and are expected to be key markets in the coming years.

Key participants in the industry include Affymetrix Inc. (U.S.), Illumina Inc. (U.S.), GE Healthcare Ltd. (U.K.), Cepheid Inc. (U.S.), Fluidigm Corporation (U.S.) and Agilent Technologies Inc. (U.S.) among others.

                                          Sample Report of Bionics Market